EANM 2023: The theranostics future is now: Innovative diagnostic application and therapeutic potential of CXCR4 

Written By Phillip Eckert

Pentixapharm to hold Symposium at EANM 2023 in Vienna

Monday, September 11, 2023 (13:15 - 14:45), Hall K 

Chairperson:

Prof. Ken Herrmann (Clinic of Nuclear Medicine University Hospital Essen)

Program:

CXCR4-directed Theranostics in Hematooncology
Speaker: Prof. Andreas Buck (Clinic of Nuclear Medicine University Hospital Würzburg)

Innovative CXCR4 directed diagnostic application in a common endocrine cause of hypertension
Speaker: Dr. Elisabeth Ng (Monash University Australia)

The Castus Trial: Aim, Design and Current Status
Speaker: Prof. Martin Gotthardt (University Medical Center Radboud University Nijmegen)

Panel Discussion

Phillip Eckert
Previous

First CNS Lymphoma Patient Dosed in Phase I/II PTT101 Study with Yttrium-90 Anditixafortide (PentixaTher)
Next

PentixaPharm Receives BfArM-Clearance for its Therapeutic to conduct a Clinical Trial in Lymphoma